Souhaitez-vous accéder aux communiqués récents ?

Pasithea adds ETS2 expert Dr. James Lee to its SAB to guide PAS-004 development for IBD and other inflammatory diseases driven by ETS2.

Abivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a...

Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK)  No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs...

Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Gastroenterology - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Gastroenterology was...

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was...

Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response ...

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis The Phase 3 ABTECT trials (Studies 105 and 106) evaluating...

The firsta approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis,1,2,3,4,5 guselkumab showed statistically higher rates of endoscopic...

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, FrancePhase 3 ABTECT...

Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and...